Published 20 November 2008, doi:10.1136/bmj.a2261
Cite this as: BMJ 2008;337:a2261

Research

Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design

¹ Finnish Cancer Registry, Pieni Roobertinkatu 9, 00130 Helsinki, Finland, ² Pirkanmaa Cancer Society, Tampere, Finland, ³ Centre for Laboratory Medicine, Pirkanmaa Hospital District, Tampere, ⁴ University of Tampere, Finland

Objectives To report the sensitivities of the faecal occult blood test, screening episode, and screening programme for colorectal cancer and the benefits of applying a randomised design at the implementation phase of a new public health policy.

Design Experimental design incorporated in public health evaluation using randomisation at individual level in the target population.

Setting 161 of the 431 Finnish municipalities in 2004-6.

Participants 106 000 adults randomised to screening or control arms. In total, 52 998 adults aged 60-64 in the screening arm received faecal occult blood test kits.

Main outcome measures Test, episode, and programme sensitivities estimated by the incidence method and corrected for selective attendance and overdiagnosis.

Results The response for screening was high overall (70.8%), and significantly better in women (78.1%) than in men (63.3%). The incidence of cancer in the controls was somewhat higher in men than in women (103 v 93 per 100 000 person years), which was not true for interval cancers (42 v 49 per 100 000 person years). The sensitivity of the faecal occult blood test was 54.6%. Only a few interval cancers were detected among those with positive test results, hence the episode sensitivity of 51.3% was close to the test sensitivity. At the population level the sensitivity of the programme was 37.5%.

Conclusions Although relatively low, the sensitivity of screening for colorectal cancer with the faecal occult blood test in Finland was adequate. An experimental design is a prerequisite for evaluation of such a screening programme because the effectiveness of preventing deaths is likely to be small and results may otherwise remain inconclusive. Thus, screening for colorectal cancer using any primary test modality should be launched in a public health programme with randomisation of the target population at the implementation phase.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Screening for colorectal cancer

Joan Austoker and Paul Hewitson
BMJ 2008 337: a2207. [Extract] [Full Text]

Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom
BMJ 2004 329: 133. [Abstract] [Full Text] [PDF]

Molecular stool screening for colorectal cancer

David A Ahlquist
BMJ 2000 321: 254-255. [Extract] [Full Text] [PDF]

A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult

Bernie Towler, Les Irwig, Paul Glasziou, Jan Kewenter, David Weller, and Chris Silagy
BMJ 1998 317: 559-565. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Austoker, J., Hewitson, P. (2008). Screening for colorectal cancer. BMJ 337: a2207-a2207 [Full text]  

Online poll

Find out more on doc2doc >>